| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $4.6M | — | -62.9% |
| SG&A Expense | $4.7M | — | -10.1% |
| Operating Income | -$9.3M | — | +47.2% |
| Net Income | -$6.3M | — | +58.6% |
| EPS (Basic) | -$4.22 | — | -1523.1% |
| EPS (Diluted) | -$4.22 | — | -1523.1% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $2.0M | -72.5% | -93.9% |
| Current Assets | $3.1M | -61.4% | -91.8% |
| Total Assets | $8.6M | -38.1% | -77.6% |
| Current Liabilities | $20.7M | -5.6% | +29.3% |
| Total Liabilities | $45.9M | -8.3% | +21.5% |
| Stockholders' Equity | -$37.3M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$5.3M | — | +67.7% |
| Financing Cash Flow | $110K | — | +127.8% |
| -6920.7% |